Evidence map›Paper›PMID 26060738›Full record

ArticleIranian journal of public health2014

Epidemiological Aspects of Hepatitis B and C Markers in Blood Donors in Kazakhstan; 2000-2011.

Nurbek Igissinov, Dariyana Kulmirzayeva, Cees Th Smit Sibinga, Asiya Turgambayeva

Open access · greenAbstract read
In one paragraph

Article in Iranian journal of public health, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Nurbek Igissinov1. Research Institute of Traumatology and Orthopedics, Astana , Kazakhstan ; 2. PA "Central Asian Cancer Institute", Astana , Kazakhstan.
Dariyana Kulmirzayeva2. PA "Central Asian Cancer Institute", Astana , Kazakhstan ; 3. JSC "Astana Medical University", Astana , Kazakhstan.
Cees Th Smit Sibinga4. Faculty of Medical Sciences, University of Groningen , Netherlands.
Asiya Turgambayeva3. JSC "Astana Medical University", Astana , Kazakhstan.
Astana Medical University · KZUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTransfusion-transmissible infections such as hepatitis B and hepatitis C are among the greatest threats to blood safety for transfusion recipients and pose a serious public health problem. The aim of this study was to assess the epidemiological aspects of hepatitis B and C in Kazakhstani donor's blood over the period 2000-2011.

methodsThe data were obtained from the annual reports of the Republican Blood Center. The retrospective study was conducted from 2000 to 2011.

resultsOver the study period in the republic a growth of volumes of procured blood from 312.4 to 398.0 units was noted, in total equaled to 4,277.8 units. The proportion of blood wasted increased from 8.3% to 8.7%. In the dynamics the proportion of viral hepatitis among all causes of blood wasted decreased from 29% to 15.5% (HBV) and from 33.5% to 9.9% (HCV). The proportion of HBV and HCV in whole blood decreased considerably, in plasma and red cell concentrate the rates changed slightly. The average annual prevalence of HBV and HCV were 2.1% and 1.8%, respectively.

conclusionDespite the reduction of viral hepatitis rates among blood donors in Kazakhstan the prevalence still remains high. The HBV prevalence is higher compared to HCV, which needs further investigations in the general population to address the issue.

Indexed as

Blood donorsHepatitis B virusHepatitis C virusKazakhstan

Identifiers

PMID26060738
PMCPMC4450682
OpenAlexW2106909083

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.